CTLA4 and Hepatitis: Anti–CTLA–4 mAbs have been associated with a higher incidence of ICI hepatitis compared to anti-PD1/anti–PD-L1 mAbs, and combination therapy was considered a higher risk than monotherapy, although our study did not demonstrate a statistically significant relationship.10,17,47 Several studies have suggested that specific histopathologic patterns may correlate with the type of ICI used.